- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07574489
Whole Versus Partial Gland Boost During Prostate SBRT
Whole Versus Partial Gland Boost During Prostate SBRT (Gland Boost)
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This is a phase 2 randomized clinical trial evaluating two dose escalation strategies during prostate stereotactic body radiotherapy (SBRT). A total of 160 patients with prostate adenocarcinoma will be enrolled and randomized in a 1:1 ratio to one of two treatment arms.
160 patients will be enrolled in this study over 3.2 years. Eligible participants will be stratified by risk group and tamsulosin use and randomized to one of two treatment arms. Both arms will receive 3625 cGy to the prostate plus planning margin delivered over 5 fractions. Arm A will receive an additional boost of 4000 cGy to the prostate alone. Arm B will receive an additional boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Acute and chronic GU and GI toxicities will be measured, as well as biochemical progression-free survival. Toxicities will be measured using CTCAE, Radiation Therapy Oncology Group, and Expanded Prostate Cancer Index Composite domains.
Participants will be followed for up to 5 years after completion of treatment.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Krishna Gottipati, MS
- Telefoonnummer: 4025593518
- E-mail: krgottipati@unmc.edu
Studie Contact Back-up
- Naam: IIT Office Gottipati
- Telefoonnummer: 4025590963
- E-mail: IITOFFICE@unmc.edu
Studie Locaties
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68198
- Fred & Pamela Buffet Cancer Center
-
Contact:
- Michael Baine, MD, PhD
- Telefoonnummer: (402) 552-2703
- E-mail: mbaine@unmc.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults ≥19 years of age
- Patients with a diagnosis of prostate adenocarcinoma for whom SBRT to the prostate +/- proximal seminal vesicles is being offered
- Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities, including MRI or CT scan
- PI-RADS 4 or 5 lesion seen on pretreatment MRI
- IPSS/AUA (Appendix D, E) symptom score less than 16
Exclusion Criteria:
- Prior treatment for prostate cancer
- Prior solid cancer diagnosis in the last 5 years
- Any history of anal or rectal cancer
- Any history of invasive carcinoma of the bladder
- History of prior circumferential resection of the rectum (such as LAR or APR)
- History of inflammatory bowel syndromes not adequately controlled on current medication regimen
- Urinary or fecal incontinence or chronic diarrhea requiring more than 1 pad per day
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm A: boost to prostate alone
Participants assigned to Arm A will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4000 cGy to the clinical target volume (CTV), consisting of the prostate alone without a margin. Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB). |
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost |
|
Experimenteel: Arm B: boost to dominant intra-prostatic lesion (DIL)
Participants assigned to Arm B will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB). |
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Grade 2 or Higher Acute Genitourinary Toxicity
Tijdsspanne: From end of treatment to 3 months post-treatment
|
To evaluate acute genitourinary (GU) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using Common Terminology Criteria for Adverse Events Version 6.0 (CTCAE) |
From end of treatment to 3 months post-treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Grade 2 or Higher Acute Gastrointestinal Toxicity
Tijdsspanne: From end of treatment to 3 months post-treatment
|
To evaluate gastrointestinal (GI) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using CTCAE |
From end of treatment to 3 months post-treatment
|
|
Biochemical Progression-Free Survival
Tijdsspanne: From initiation of study treatment to 5 years post-treatment
|
Time from initiation of study treatment to biochemical disease progression or death from any cause |
From initiation of study treatment to 5 years post-treatment
|
|
Chronic Gastrointestinal Toxicity - Cumulative Incidence
Tijdsspanne: From 6 months to 21 months post-treatment
|
Cumulative incidence of chronic gastrointestinal (GI) toxicities assessed using CTCAE, Radiation Therapy Oncology Group (RTOG), and Expanded Prostate Cancer Index Composite (EPIC) domains. |
From 6 months to 21 months post-treatment
|
|
Chronic Genitourinary Toxicity - Cumulative Incidence
Tijdsspanne: From 6 months to 21 months post-treatment
|
Cumulative incidence of chronic genitourinary (GU) toxicities assessed using CTCAE, RTOG, and EPIC domains. |
From 6 months to 21 months post-treatment
|
|
Chronic Gastrointestinal Toxicity
Tijdsspanne: At 5 years
|
To evaluate chronic GI toxicities at 5 years using CTCAE, RTOG, and EPIC domains. |
At 5 years
|
|
Chronic Genitourinary Toxicity
Tijdsspanne: At 5 years
|
To evaluate chronic GU toxicities at 5 years using CTCAE, RTOG, and EPIC domains. |
At 5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Michael Baine, MD, PhD, University of Nebraska medicine
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Gland Boost
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .